Recent Finacing
Recent Raise
Advaccine develops DNA vaccines (INO‑4800 COVID‑19, RSV, hepatitis B), co-develops INO‑4800 with Inovio, runs phase 2 trials and a Suzhou facility producing 20–100M doses annually with extended refrigerated stability.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Advaccine.
